June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Performance of automated hyperemia assessment in allergic conjunctivitis interventional study
Author Affiliations & Notes
  • Michael J Wald
    Translational Medicine, Novartis Institutes for BioMedical Research, Inc., Cambridge, MA
  • Bruno Lay
    ADCIS, Saint-Contest, France
  • Ronan Danno
    ADCIS, Saint-Contest, France
  • Cynthia L Grosskreutz
    Translational Medicine, Novartis Institutes for BioMedical Research, Inc., Cambridge, MA
  • Sudeep Chandra
    Translational Medicine, Novartis Institutes for BioMedical Research, Inc., Cambridge, MA
  • Footnotes
    Commercial Relationships Michael Wald, Novartis Institutes for BioMedical Research, Inc. (E); Bruno Lay, Novartis Institutes for BioMedical Research, Inc. (C); Ronan Danno, Novartis Institutes for BioMedical Research, Inc. (C); Cynthia Grosskreutz, Novartis Institutes for BioMedical Research, Inc. (E); Sudeep Chandra, Novartis Institutes for BioMedical Research, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4041. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael J Wald, Bruno Lay, Ronan Danno, Cynthia L Grosskreutz, Sudeep Chandra; Performance of automated hyperemia assessment in allergic conjunctivitis interventional study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4041.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular hyperemia is an important efficacy, safety, and tolerability endpoint in ophthalmic clinical trials. Subjective scoring of ocular hyperemia can vary over time and suffers from inter-grader variability. A novel automated approach called Imaging System for Ocular Surface (ISOS) was applied in a double-blind interventional study in allergic conjunctivitis to explore its reproducibility and sensitivity.

Methods: Twenty three subjects allergic to ragweed pollen were assessed by slit lamp photography after seven days of either 0.1% Maxidex ophthalmic suspension (n=13) or vehicle control (n=10) BID. Photographs were acquired before and after three hours in a ragweed pollen environmental exposure chamber (EEC) with study medication being administered just before entering EEC. Each image was immediately scored by an ophthalmologist and later by three fully-blinded expert graders following the validated bulbar redness scale from 0 to 4 in 0.5 increments. A consensus expert score for each photograph was calculated to minimize the influence of each grader’s intrinsic variability which was estimated via modeling and repeat scoring. Photographs were processed using an automatic vessel segmentation algorithm to quantify 35 morphological descriptors of the conjunctival vasculature which were then input into multivariate linear regression models of live and expert consensus scores. The sensitivity to Maxidex treatment was explored for all hyperemia scores and image descriptors using a linear mixed model of change from pre-EEC.

Results: Vessel density alone was the best predictor of live hyperemia score (r=0.68) whereas the consensus expert score was best fit by a linear model of fourteen morphological descriptors (r=0.93) including vessel density. The resulting automated hyperemia score was within 0.36 units (95% CI) of its absolute score versus 0.34, 0.64, and 0.42-0.56 for expert consensus, live, and individual expert scores, respectively. Subjects receiving Maxidex experienced a stronger decrease in hyperemia than vehicle control per consensus expert score (p<0.05), automated score (p<0.05), vessel density (p<0.05), number of triple points (p<0.05), and total vessel length (p<0.05).

Conclusions: ISOS-based hyperemia assessment demonstrated similar robustness as the consensus of three experts and offered improved sensitivity to treatment via the characterization of vessel morphology.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×